ABSTRACT
Silent information regulators are a family of highly conserved nicotinamide adenine dinucleotide (NAD+)-dependent deacetylases and has seven members (Sirt1-7). Silent information regulator 4 (Sirt4), localized in the mitochondria, possesses the activity of deacetylase, ADP-ribosyltransferase, NAD+-dependent lipoamidase, and deacylase, participates in post-translational modification of mitochondrial proteins, and regulates multiple metabolic processes. Since metabolic dysfunction is closely associated with liver diseases, the role and regulatory mechanism of Sirt4 in liver diseases has attracted more and more attention. This article elaborates on the role of Sirt4 in viral hepatitis, nonalcoholic fatty liver disease, liver fibrosis, and hepatocellular carcinoma, in order to provide new perspectives for the prevention and treatment of these liver diseases.
ABSTRACT
Objective To evaluate Chinese clinical practice guideline/consensus for digestive diseases published in the past five years in order to recommend the high-quality guidelines and help with the promotion and implementation of them.Methods From January 2013 to June 2018,the officially published Chinese practice guideline/consensus for digestive diseases were selected.The inclusion and exclusion criteria of the guideline/consensus was evaluated by " Evaluation Criteria for Chinese Clinical Practice Guidelines 2017 (AGREE-China 2017)".The guideline/consensus were independently scored by three evaluators and then calculated the average value.Descriptive analysis methods were used to analyze the Chinese clinical practice guideline/consensus for digestive diseases.Those with the total score more than 40.0 points were included in the recommended list.Results A total of 119 officially published clinical practice guideline/consensus of digestive diseases were retrieved,and 74 clinical practice guideline/consensus for digestive diseases were included in the evaluation.Among them,18 (24.3％,18/74) scored over 60.0 points,31 (41.9％,31/74) scored between 40.0 and 59.9 points.Finally 48 guideline or consesus were selected for the recommended list 19 cases of esophagus and gastrointestinal diseases,18 cases of liver diseases,five cases of biliary and pancreafic diseases,and six cases of digestive endoscopy.The three guideline/consensus with the high scores (＞ 80.0 points) were The Fifth Chinese National Consensus Report on the Maragement of Helicobacter pylori Infection,Consensus on the Diagnosis and Treatmeat of Cholestatic Liver Disease (2015) and Guidelines for the Prevention and Treatment of Chroaic Hepatitis B (2015 Update).The higher the score of the guideline/consensus,the more scientific and rigorous the method,and the clearer the evaluation of evidence grade and the description of the formation of recommendations.Compared with international standards of guideline/consensus development,there are still some problems in Chinese guidelines or consensus such as no explanation of retrieval strategy,no basis of evidence classification and no description of the formation process from evidence to recommendation.Conclusions The quality of Chinese clinical practice guideline/consensus for digestive diseases has been improved year by year.However the scientific aspects need to be further improved.AGREE-China which demonstrates good validity,realiability and practicability is easy and clear to use.
ABSTRACT
Objective@#To evaluate Chinese clinical practice guideline/consensus for digestive diseases published in the past five years in order to recommend the high-quality guidelines and help with the promotion and implementation of them.@*Methods@#From January 2013 to June 2018, the officially published Chinese practice guideline/consensus for digestive diseases were selected. The inclusion and exclusion criteria of the guideline/consensus was evaluated by "Evaluation Criteria for Chinese Clinical Practice Guidelines 2017(AGREE-China 2017)" . The guideline/consensus were independently scored by three evaluators and then calculated the average value. Descriptive analysis methods were used to analyze the Chinese clinical practice guideline/consensus for digestive diseases. Those with the total score more than 40.0 points were included in the recommended list.@*Results@#A total of 119 officially published clinical practice guideline/consensus of digestive diseases were retrieved, and 74 clinical practice guideline/consensus for digestive diseases were included in the evaluation. Among them, 18 (24.3%, 18/74) scored over 60.0 points, 31 (41.9%, 31/74) scored between 40.0 and 59.9 points. Finally 48 guideline or consesus were selected for the recommended list 19 cases of esophagus and gastrointestinal diseases, 18 cases of liver diseases, five cases of biliary and pancreafic diseases, and six cases of digestive endoscopy. The three guideline/consensus with the high scores (> 80.0 points) were The Fifth Chinese National Consensus Report on the Maragement of Helicobacter pylori Infection, Consensus on the Diagnosis and Treatmeat of Cholestatic Liver Disease (2015) and Guidelines for the Prevention and Treatment of Chroaic Hepatitis B (2015 Update). The higher the score of the guideline/consensus, the more scientific and rigorous the method, and the clearer the evaluation of evidence grade and the description of the formation of recommendations. Compared with international standards of guideline/consensus development, there are still some problems in Chinese guidelines or consensus such as no explanation of retrieval strategy, no basis of evidence classification and no description of the formation process from evidence to recommendation.@*Conclusions@#The quality of Chinese clinical practice guideline/consensus for digestive diseases has been improved year by year. However the scientific aspects need to be further improved. AGREE-China which demonstrates good validity, realiability and practicability is easy and clear to use.
ABSTRACT
Silent information regulators are a family of highly conserved nicotinamide adenine dinucleotide (NAD+)-dependent deacetylases and has seven members (Sirt1-7). Silent information regulator 4 (Sirt4), localized in the mitochondria, possesses the activity of deacetylase, ADP-ribosyltransferase, NAD+-dependent lipoamidase, and deacylase, participates in post-translational modification of mitochondrial proteins, and regulates multiple metabolic processes. Since metabolic dysfunction is closely associated with liver diseases, the role and regulatory mechanism of Sirt4 in liver diseases has attracted more and more attention. This article elaborates on the role of Sirt4 in viral hepatitis, nonalcoholic fatty liver disease, liver fibrosis, and hepatocellular carcinoma, in order to provide new perspectives for the prevention and treatment of these liver diseases.